5 citations,
December 2022 in “Annals Academy of Medicine Singapore” Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.
October 2023 in “Microorganisms” Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.
May 2023 in “Clinical and translational neuroscience” Tailored neurorehabilitation programs improve life quality for post-COVID-19 patients.
8 citations,
March 2023 in “Journal of Clinical Epidemiology” The updated GRADE guidance advises considering context when interpreting variability in research results and introduces tools for assessing subgroup effects.